LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) has entered into definitive agreements with accredited investors for a registered direct offering that is expected to generate approximately $16.6 million in gross proceeds, the company announced. The offering consists of 2,625,362 shares of common stock and pre-funded warrants, priced at $6.31 per share, with the transaction priced at the market under Nasdaq rules.
The financing materially strengthens LIXTE's balance sheet and provides additional flexibility to pursue strategic priorities, the company said. LIXTE expects the offering to close on or about June 3, 2026, subject to customary closing conditions, and plans to use the net proceeds for general corporate purposes, working capital and strategic initiatives.
Chief Executive Officer Geordan Pursglove said the financing positions the company for its next phase of growth and follows the recent appointment of Denham Capital founder Stuart Porter to the company’s board of directors. For more details, view the full press release at https://ibn.fm/rHL1p.
LIXTE Biotechnology Holdings is a clinical-stage pharmaceutical and med-tech company focused on new targets for cancer drug development and developing and commercializing cancer therapies. LIXTE has demonstrated that LB-100, its lead compound and first-in-class lead clinical PP2A inhibitor, is well-tolerated in cancer patients at doses associated with anti-cancer activity. Based on published preclinical data, LB-100 has the potential to significantly enhance chemotherapies and immunotherapies and improve outcomes for patients with cancer. It is part of a pioneering effort in an entirely new field of cancer biology – activation lethality – that is advancing a new treatment paradigm. LIXTE’s novel approach is covered by a comprehensive patent portfolio, with proof-of-concept clinical trials currently in progress for Ovarian Clear Cell Carcinoma, Metastatic Colon Cancer and Advanced Soft Tissue Sarcoma.
Through LIXTE’s wholly owned subsidiary, Liora Technologies Europe Ltd., the Company also is pioneering the development of electronically controlled proton therapy systems for treating tumors in various types of cancers. Liora’s proprietary flagship technology, LiGHT System, is believed to provide significant advantages over currently available technologies for treating tumors with proton therapy. Additional information about Liora Technologies can be found at www.lioratechnologies.com.
This offering is significant for investors as it provides LIXTE with the capital necessary to advance its clinical programs and strategic initiatives, potentially impacting the cancer treatment landscape. The company’s focus on PP2A inhibition and proton therapy represents novel approaches that could offer new options for patients with difficult-to-treat cancers. The financing also signals confidence from accredited investors and positions LIXTE for its next growth phase.
